Clinical Trials Logo

Colon Cancer Stage III clinical trials

View clinical trials related to Colon Cancer Stage III.

Filter by:
  • None
  • Page 1

NCT ID: NCT06108310 Recruiting - Clinical trials for Colon Cancer Stage III

ArTificial inTelligence-based RAdiogenomics in Colon Tumors

ATTRACT
Start date: January 2, 2021
Phase:
Study type: Observational

The goal of this clinical trial is to develop an artificial intelligence-based model to assess radiogenomics signature of colon tumor in patients with stage II-III colon cancer. The main question it aims to answer is: • Can artificial intelligence-based algorithm of radiomics features combined with clinical factors, biochemical biomarkers, and genomic data recognise tumor behaviour, aggressiveness, and prognosis, identifying a radiogenomics signature of the tumor? Participants will - undergo a preoperative contrast-enhanced CT examination; - undergo surgical excision of colon cancer - undergo adjuvant therapy if deemed necessary based on current guidelines

NCT ID: NCT05433402 Withdrawn - Clinical trials for Colon Cancer Stage III

Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer

Start date: July 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis, induction of cytotoxic autophagy, inhibition of glutamate and DRD2 receptors. This study will evaluate the addition of chlorpromazine to the first-line therapeutic protocol in colon cancer stage III.

NCT ID: NCT05310565 Withdrawn - Clinical trials for Colon Cancer Stage III

The Effects of Chiropractic in Adults With Colon Cancer

CCX
Start date: January 1, 2025
Phase: N/A
Study type: Interventional

The main objectives of this single-arm pilot trial are to investigate the feasibility of our protocol in terms of 1) recruitment, 2) adherence, 3) tolerability, 4) acceptability and 5) retention. We aim to recruit 20 participants with advanced colon cancer (stage 3-4) who will have assessments of their autonomic nervous system function, carcinoembryonic antigen (CEA) levels, and patient-reported outcomes. Thereafter, patients will be directed to a nearby field clinic to receive twice-weekly cervical assessments & high-velocity, low-amplitude (HVLA) cervical adjustments for a period of 6 weeks. Re-assessments will be performed following 2 weeks and 6 weeks of chiropractic care.

NCT ID: NCT05194878 Recruiting - Clinical trials for Colon Cancer Stage III

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Start date: December 1, 2021
Phase: Phase 3
Study type: Interventional

BACKGROUND: In patients with high risk stage II and stage III colon cancer (CC), curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become a standard treatment. However, 20 to 30 % of these patients will develop distant metastasis, which ultimately result in death. Perioperative chemotherapy is a promising strategy with potential benefits that could be more effective at eradicating micrometastases. Moreover, shrinking tumor before surgery not only facilitate removal of all the tumor by the surgeon but also reduce tumor cell spreading during the procedure. With recent advances in radiology, preoperative computed tomography allows a good prediction of tumor stage (wall penetration and nodal involvement) prior to surgery. The investigators conducted the present randomized study to explore whether perioperative chemotherapy with FOLFOXIRI regimen compared with postoperative chemotherapy could improve disease-free survival in patients with radiologically staged, High-risk, but resectable Stage II or III colon cancer. OBJECTIVE: The primary objective of this study is to evaluate the efficacy of perioperative chemotherapy with FOLFOXIRI regimen compared to postoperative chemotherapy in patients with High-risk Resectable Stage II and III colon cancer. Secondary objectives are efficacy in terms of R0 resection rate, overall survival (OS), relapse-free survival (RFS), down-staging of primary tumors, and tolerability of perioperative therapy and postoperative complications.

NCT ID: NCT05179889 Enrolling by invitation - Clinical trials for Colon Cancer Stage III

Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer

Start date: July 6, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

A multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer

NCT ID: NCT04907643 Recruiting - Rectal Cancer Clinical Trials

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Start date: October 5, 2021
Phase: N/A
Study type: Interventional

Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Users of VR wear a pair of goggles with a close-proximity screen in front of the eyes that creates a sensation of being transported into lifelike, three-dimensional worlds. To date, VR has been limited to short-term clinical trials for cancer pain. Moreover, limited research exists on theory-based VR modalities beyond mere distraction, such as VR that employs acceptance and commitment therapy (ACT) with components of biofeedback and mindfulness. To bridge these gaps, this study seeks to: (1) assess the impact of immersive VR on patient-reported outcomes (PROs), including pain, activity metrics, and opioid use among patients with visceral pain from a digestive tract malignancy; (2) assess differences in PROs, activity metrics, and opioid use between skills-based VR therapy vs. distraction VR therapy; and (3) determine patient-level predictors of VR treatment response in visceral cancer pain. To address these aims, the study will measure PROs and opioid use in 360 patients randomized among 3 groups and follow them for 60 days after enrollment: (1) an enhanced VR group receiving skills-based VR; (2) a distraction-based VR group receiving patient-selected VR videos; and (3) a VR sham control group using a VR headset with 2-D content. The results will inform best practices for the implementation of VR for visceral cancer pain management and guide selection of patient-tailored experiences.

NCT ID: NCT04488159 Not yet recruiting - Clinical trials for Colon Cancer Stage III

Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer

iMAGINE
Start date: December 1, 2024
Phase: Phase 3
Study type: Interventional

The overall aim of this study is to prospectively validate the superiority of the Immunoscore as a decision guidance for adjuvant chemotherapy in stage III colon cancer patients, in comparison to the conventional TNM-based high- or low-risk classification.

NCT ID: NCT04342676 Completed - Clinical trials for Colon Cancer Stage III

Lymph Node Ratio and Kras Mutation in R Colon Cancer

Start date: March 10, 2017
Phase: Phase 3
Study type: Interventional

clinical impact of LN ratio with Kras expression in colon cancer

NCT ID: NCT00309530 Completed - Clinical trials for Colon Cancer Stage III

Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C

Start date: October 1990
Phase: Phase 3
Study type: Interventional

This clinical investigation examined the effectivity 5-fluorouracil, of adding levamisol or interferon to 5-fluorouracil, and of a 5-fluorouracil/levamisol/interferon triple combination, in terms of recurrence-free and overall survival in curatively operable colon carcinoma Stage III.